APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Study sponsor: Aprea Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-08-27Actual
Enrollment · participants33Actual
Source updated2025-03-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.